Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
about
Applications of CYP450 testing in the clinical settingEffects of CYP2D6 and CYP3A5 polymorphisms on tamoxifen and its metabolites in Thai breast cancer patients.Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.Concomitant use of tamoxifen and endoxifen in postmenopausal early breast cancer: prediction of plasma levels by physiologically-based pharmacokinetic modeling.Influence of the length and positioning of the antiestrogenic side chain of endoxifen and 4-hydroxytamoxifen on gene activation and growth of estrogen receptor positive cancer cells.PharmGKB summary: tamoxifen pathway, pharmacokineticsHigh-throughput and combinatorial gene expression on a chip for metabolism-induced toxicology screening.Tamoxifen and CYP2D6: a contradiction of data.Use of CYP2D6 genotyping in practice: tamoxifen dose adjustment.Effects of CYP induction by rifampicin on tamoxifen exposure.Individualization of tamoxifen treatment for breast carcinoma.Endoxifen, a New Treatment Option for Mania: A Double-Blind, Active-Controlled Trial Demonstrates the Antimanic Efficacy of EndoxifenPopulation pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifenLinking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy.Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients.Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patientsSimulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study NetworkPharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies.Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.Pharmacogenomic diversity of tamoxifen metabolites and estrogen receptor genes in Hispanics and non-Hispanic whites with breast cancer.SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer PatientsLimited predictive value of achieving beneficial plasma (Z)-endoxifen threshold level by CYP2D6 genotyping in tamoxifen-treated Polish women with breast cancer.Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Clinical and biomarker predictors of side effects from tamoxifenPhysiologically Based Pharmacokinetic Modeling of Tamoxifen and its Metabolites in Women of Different CYP2D6 Phenotypes Provides New Insight into the Tamoxifen Mass Balance.Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifenProfound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report.Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.Role of cytochrome P450 genotype in the steps toward personalized drug therapy.Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations.CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8.Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI SwitchPotential role of UGT1A4 promoter SNPs in anastrozole pharmacogenomicsVariants in tamoxifen metabolizing genes: a case-control study of contralateral breast cancer risk in the WECARE study.
P2860
Q24621760-74029B47-9CE4-4B0B-868B-F79B17CC39F9Q33589336-8683A119-4B42-4049-8C3A-1C1A8C987C70Q33705490-B9FCE3B0-820E-4C22-B181-32542C6E70E9Q33756964-C748B14D-E650-47C1-88B8-066E17F6D942Q33761834-8584A938-60BD-43B3-B71A-D321636D992CQ33855494-F5001B8C-8053-48A6-8BBB-650A1328A94AQ34044936-9FB7FB48-E6EB-49E4-9BBC-7A132137A139Q34244463-8E84EE60-E93D-4A40-9B14-5F331ED99963Q34269380-68035E84-F69F-4E75-8CDD-302B3459C814Q34278391-6665CB35-2DC7-4998-ABF5-A38927047562Q34387066-060F97CA-10F6-4E87-8542-00D5037DE88EQ34532071-3517EE8D-B947-4839-8ED5-7BA3457415C1Q34571065-29B63CFF-6A1A-471B-9BD0-D8C4CEDE0EE4Q34736075-D3FF0ABC-B05A-4BF4-BBBE-28FA63EA58B4Q34736986-F9F6A78D-6F3F-4381-A543-87077E12B7D5Q34906432-C4028F7D-0433-40C0-BF31-C49562A924DFQ34914140-7E1AE1E5-0C03-494B-9CEE-935E8575AD40Q35020403-66C2CAC8-964C-463A-85A8-2DB3964689B7Q35054455-CEC1F53D-C703-4F89-B8F4-073DE97438A0Q35129546-788DD251-489B-417D-B069-25B96F91958BQ35168556-3371AE10-61B6-4DB1-80A2-83E42EFC86D9Q35551039-FF84ACF0-D9F9-40EC-8910-67EB1BC4A88DQ35605304-4AD7D8DC-A981-42E3-A60D-8423BCC49746Q35691825-754FA306-0454-4166-8571-33089F0C7E92Q35732619-3B4CABC8-9AFF-4233-A278-B6F480315418Q35747766-7862F436-BAF5-4607-922C-36AAAEB2A3C1Q35884159-B0816CC6-180C-4F37-A692-9C9657A2967BQ35911174-03732503-283C-4677-99F2-95C956DA8626Q35975826-10920627-733C-49DF-A23E-C5842C903B8CQ35996187-A637892A-6DF1-499A-9293-D19FA2EA13E6Q36015010-3733FACE-66DD-4E05-B87E-1065C2ABD693Q36047387-78B15FC9-DCAA-4F40-AEE1-2C5C6EC3A29FQ36243663-E45E9022-7D3A-4040-B164-07F04F21ABA5Q36441521-15CF6796-6DC6-4F9A-BF2B-6D03334930CBQ36517144-19672EEE-28DF-49FF-A689-6A9177B1FDC1Q36545056-52F31E3A-27F4-403C-8D11-E60181F7763BQ36550926-4D52D077-E24C-401B-B26C-F13E80459A66Q36586900-78F813F4-FF9B-48CE-9729-062FF44E69ECQ36717159-61C00AFC-8D0C-4DAF-9A2E-96223181837DQ36729040-651675CB-8AD0-47A4-9D65-88B9BC66109B
P2860
Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
description
article
@en
im März 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в березні 2011
@uk
name
Activity Levels of Tamoxifen M ...... Concentration Levels in Plasma
@en
Activity Levels of Tamoxifen M ...... Concentration Levels in Plasma
@nl
type
label
Activity Levels of Tamoxifen M ...... Concentration Levels in Plasma
@en
Activity Levels of Tamoxifen M ...... Concentration Levels in Plasma
@nl
prefLabel
Activity Levels of Tamoxifen M ...... Concentration Levels in Plasma
@en
Activity Levels of Tamoxifen M ...... Concentration Levels in Plasma
@nl
P2093
P2860
P356
P1476
Activity Levels of Tamoxifen M ...... Concentration Levels in Plasma
@en
P2093
G Heinkele
L Bacchus-Gerybadze
M Eichelbaum
T E Mürdter
P2860
P304
P356
10.1038/CLPT.2011.27
P407
P577
2011-03-30T00:00:00Z